In conclusion, adiponectin is a promising target for hepatic insulin resistance and resultantly metabolic disorder, but further clinical research is required to translate similar impacts in humans keeping in mind the pleiotropic nature of this hormone. Here, ADIPOQ is linked to Insulin resistance.